{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:44:10Z","timestamp":1777502650323,"version":"3.51.4"},"reference-count":50,"publisher":"Oncology Nursing Society (ONS)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ONF"],"published-print":{"date-parts":[[2016,3,1]]},"DOI":"10.1188\/16.onf.227-234","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T14:55:11Z","timestamp":1455893711000},"page":"227-234","source":"Crossref","is-referenced-by-count":2,"title":["Nursing Roles in Cardiac Safety: Romidepsin in Patients With T-Cell Lymphoma"],"prefix":"10.1188","volume":"43","author":[{"given":"Jan","family":"Hronek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2016,3,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Benoit, S.R., Mendelsohn, A.B., Nourjah, P., Staffa, J.A., & Graham, D.J. (2005). Risk factors for prolonged QTc among US adults: Third National Health and Nutrition Examination Survey. European Journal of Cardiovascular Prevention and Rehabilitation, 12, 363\u2013368. doi:10.1097\/01.hjr.0000173110.21851.a9\u00a0","DOI":"10.1097\/01.hjr.0000173110.21851.a9"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Bolden, J.E., Peart, M.J., & Johnstone, R.W. (2006). Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery, 5, 769\u2013784. doi:10.1038\/nrd2133","DOI":"10.1038\/nrd2133"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bradner, J.E., West, N., Grachan, M.L., Greenberg, E.F., Haggarty, S.J., Warnow, T., & Mazitschek, R. (2010). Chemical phylogenetics of histone deacetylases. Nature Chemical Biology, 6, 238\u2013243. doi:10.1038\/nchembio.313","DOI":"10.1038\/nchembio.313"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Brygger, L., & Herrstedt, J. (2014). 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opinion on Drug Safety, 13, 1407\u20131422. doi:10.1517\/14740338.2014.954546","DOI":"10.1517\/14740338.2014.954546"},{"key":"5","unstructured":"Celgene Corporation. (2014). Istodax\u00ae (romidepsin) [Package insert]. Summit, NJ: Author."},{"key":"6","doi-asserted-by":"crossref","unstructured":"Coiffier, B., Pro, B., Prince, H.M., Foss, F., Sokol, L., Greenwood, M., . . . Horwitz, S. (2012). Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal of Clinical Oncology, 30, 631\u2013636. doi:10.1200\/JCO.2011.37.4223","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Coiffier, B., Pro, B., Prince, H.M., Foss, F., Sokol, L., Greenwood, M., . . . Horwitz, S. (2014). Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses. Journal of Hematology and Oncology, 7, 11. doi:10.1186\/1756-8722-7-11","DOI":"10.1186\/1756-8722-7-11"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Del Gobbo, L.C., Imamura, F., Wu, J.H., de Oliveira Otto, M.C., Chiuve, S.E., & Mozaffarian, D. (2013). Circulating and dietary magnesium and risk of cardiovascular disease: A systematic review and meta-analysis of prospective studies. American Journal of Clinical Nutrition, 98, 160\u2013173. doi:10.3945\/ajcn.112.053132","DOI":"10.3945\/ajcn.112.053132"},{"key":"9","unstructured":"El-Sherif, N., & Turitto, G. (2011). Electrolyte disorders and arrhythmogenesis. Cardiology Journal, 18, 233\u2013245."},{"key":"10","doi-asserted-by":"crossref","unstructured":"Gonullu, G., Demircan, S., Demirag, M.K., Erdem, D., & Yucel, I. (2012). Electrocardiographic findings of palonosetron in cancer patients. Supportive Care in Cancer, 20, 1435\u20131439. doi:10.1007\/s00520-011-1226-5","DOI":"10.1007\/s00520-011-1226-5"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Iyer, S.P., & Foss, F.F. (2015). Romidepsin for the treatment of peripheral T-cell lymphoma. Oncologist, 20, 1084\u20131091. doi:10.1634\/theoncologist.2015-0043","DOI":"10.1634\/theoncologist.2015-0043"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Jin, Y., Sun, W., Gu, D., Yang, J., Xu, Z., & Chen, J. (2013). Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: A meta-analysis. European Journal of Cancer Care, 22, 41\u201350. doi:10.1111\/j.1365-2354.2012.01353.x","DOI":"10.1111\/j.1365-2354.2012.01353.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Keefe, D.L. (2002). The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: Is there cause for concern? Oncologist, 7, 65\u201372. doi:10.1634\/theoncologist.7-1-65","DOI":"10.1634\/theoncologist.7-1-65"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Khan, O., & La Thangue, N.B. (2012). HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunology and Cell Biology, 90, 85\u201394. doi:10.1038\/icb.2011.100","DOI":"10.1038\/icb.2011.100"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Kristeleit, R., Fong, P., Aherne, G.W., & de Bono, J. (2005). Histone deacetylase inhibitors: Emerging anticancer therapeutic agents? Clinical Lung Cancer, 7(Suppl. 1), S19\u2013S30. doi:10.3816\/clc.2005.s.004","DOI":"10.3816\/CLC.2005.s.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Marshall, J.L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M.H., . . . Hawkins, M.J. (2002). A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. Journal of Experimental Therapeutics and Oncology, 2, 325\u2013332. doi:10.1046\/j.1359-4117.2002.01039.x\u00a0","DOI":"10.1046\/j.1359-4117.2002.01039.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Marsoni, S., Damia, G., & Camboni, G. (2008). A work in progress: The clinical development of histone deacetylase inhibitors. Epigenetics, 3, 164\u2013171. doi:10.4161\/epi.3.3.6253\u00a0","DOI":"10.4161\/epi.3.3.6253"},{"key":"18","unstructured":"Mayo Clinic Staff. (2015). Long QT syndrome: Symptoms. Retrieved from http:\/\/www.mayoclinic.org\/diseases-conditions\/long-qt-syndrome\/basics\/symptoms\/con-20025388"},{"key":"19","unstructured":"Merck & Co, Inc. (2013). Zolinza\u00ae (vorinostat) [Package insert]. Whitehouse Station, NJ: Author."},{"key":"20","doi-asserted-by":"crossref","unstructured":"Mizusawa, Y., Horie, M., & Wilde, A.A. (2014). Genetic and clinical advances in congenital long QT syndrome. Circulation Journal, 78, 2827\u20132833. doi:10.1253\/circj.cj-14-0905\u00a0","DOI":"10.1253\/circj.CJ-14-0905"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Molife, R., Fong, P., Scurr, M., Judson, I., Kaye, S., & de Bono, J. (2007). HDAC inhibitors and cardiac safety. Clinical Cancer Research, 13, 1068. doi:10.1158\/1078-0432.ccr-06-2380\u00a0","DOI":"10.1158\/1078-0432.CCR-06-2380"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Morgan, M., Maloney, D., & Duvic, M. (2002). Hypomagnesemia and hypocalcemia in mycosis fungoides: A retrospective case series. Leukemia and Lymphoma, 43, 1297\u20131302. doi:10.1080\/10428190290026367\u00a0","DOI":"10.1080\/10428190290026367"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Napolitano, C., Priori, S.G., & Schwartz, P.J. (1994). Torsade de pointes. Mechanisms and management. Drugs, 47, 51\u201365. doi:10.2165\/00003495-199447010-00004","DOI":"10.2165\/00003495-199447010-00004"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Navari, R.M., & Koeller, J.M. (2003). Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Annals of Pharmacotherapy, 37, 1276\u20131286. doi:10.1345\/aph.1c510\u00a0","DOI":"10.1345\/aph.1C510"},{"key":"25","doi-asserted-by":"crossref","unstructured":"New, M., Olzscha, H., & La Thangue, N.B. (2012). HDAC inhibitor-based therapies: Can we interpret the code? Molecular Oncology, 6, 637\u2013656. doi:10.1016\/j.molonc.2012.09.003","DOI":"10.1016\/j.molonc.2012.09.003"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Noonan, A.M., Eisch, R.A., Liewehr, D.J., Sissung, T.M., Venzon, D.J., Flagg, T.P., . . . Bates, S.E. (2013). Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for KATP channel. Clinical Cancer Research, 19, 3095\u20133104. doi:10.1158\/1078-0432.CCR-13-0109","DOI":"10.1158\/1078-0432.CCR-13-0109"},{"key":"27","unstructured":"Novartis Pharmaceuticals Corporation. (2015). Farydak\u00ae (panobinostat) [Package insert]. East Hanover, NJ: Author."},{"key":"28","doi-asserted-by":"crossref","unstructured":"Osadchii, O.E. (2010). Mechanisms of hypokalemia-induced ventricular arrhythmogenicity. Fundamental and Clinical Pharmacology, 24, 547\u2013559. doi:10.1111\/j.1472-8206.2010.00835.x","DOI":"10.1111\/j.1472-8206.2010.00835.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Peacock, J.M., Ohira, T., Post, W., Sotoodehnia, N., Rosamond, W., & Folsom, A.R. (2010). Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) study. American Heart Journal, 160, 464\u2013470. doi:10.1016\/j.ahj.2010.06.012","DOI":"10.1016\/j.ahj.2010.06.012"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Piekarz, R.L., Frye, A.R., Wright, J.J., Steinberg, S.M., Liewehr, D.J., Rosing, D.R., . . . Bates, S.E. (2006). Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clinical Cancer Research, 12, 3762\u20133773. doi:10.1158\/1078-0432.ccr-05-2095\u00a0","DOI":"10.1158\/1078-0432.CCR-05-2095"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Piekarz, R.L., Frye, R., Prince, H.M., Kirschbaum, M.H., Zain, J., Allen, S.L., . . . Bates, S.E. (2011). Phase II trial of romidepsin in patients with peripheral T-cell lymphoma. Blood, 117, 5827\u20135834. doi:10.1182\/blood-2010-10-312603","DOI":"10.1182\/blood-2010-10-312603"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Piekarz, R.L., Frye, R., Turner, M., Wright, J.J., Allen, S.L., Kirschbaum, M.H., . . . Bates, S.E. (2009). Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology, 27, 5410\u20135417. doi:10.1200\/JCO.2008.21.6150","DOI":"10.1200\/JCO.2008.21.6150"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Rawlinson, A., Kitchingham, N., Hart, C., McMahon, G., Ong, S.L., & Khanna, A. (2012). Mechanisms of reducing postoperative pain, nausea and vomiting: A systematic review of current techniques. Evidence-Based Medicine, 17, 75\u201380. doi:10.1136\/ebmed-2011-100265","DOI":"10.1136\/ebmed-2011-100265"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Roden, D.M. (1997). A practical approach to torsade de pointes. Clinical Cardiology, 20, 285\u2013290. doi:10.1002\/clc.4960200318\u00a0","DOI":"10.1002\/clc.4960200318"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Sager, P.T. (2008). Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes. British Journal of Pharmacology, 154, 1544\u20131549. doi:10.1038\/bjp.2008.222","DOI":"10.1038\/bjp.2008.222"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Sager, P.T., Balser, B., Wolfson, J., Nichols, J., Pilot, R., Jones, S., & Burris, H.A. (2015). Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin. Cancer Medicine, 4, 1178\u20131185. doi:10.1002\/cam4.467","DOI":"10.1002\/cam4.467"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Salvo, N., Doble, B., Khan, L., Amirthevasar, G., Dennis, K., Pasetka, M., . . . Chow, E. (2012). Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: A systematic review of randomized trials. International Journal of Radiation Oncology, Biology, Physics, 82, 408\u2013417. doi:10.1016\/j.ijrobp.2010.08.060","DOI":"10.1016\/j.ijrobp.2010.08.060"},{"key":"38","unstructured":"Sandor, V., Bakke, S., Robey, R.W., Kang, M.H., Blagosklonny, M.V., Bender, J., . . . Bates, S.E. (2002). Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clinical Cancer Research, 8, 718\u2013728."},{"key":"39","doi-asserted-by":"crossref","unstructured":"Santoro, A., Mancini, E., London, G., Mercadal, L., Fessy, H., Perrone, B., . . . Cavalcanti, S. (2008). Patients with complex arrhythmias during and after haemodialysis suffer from different regimens of potassium removal. Nephrology, Dialysis, Transplantation, 23, 1415\u20131421. doi:10.1093\/ndt\/gfm730\u00a0","DOI":"10.1093\/ndt\/gfm730"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Sarapa, N., & Britto, M.R. (2008). Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents. Expert Opinion on Drug Safety, 7, 305\u2013318. doi:10.1517\/14740338.7.3.305","DOI":"10.1517\/14740338.7.3.305"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Shah, M.H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M., . . . Grever, M. (2006). Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clinical Cancer Research, 12, 3997\u20134003. doi:10.1158\/1078-0432.ccr-05-2689\u00a0","DOI":"10.1158\/1078-0432.CCR-05-2689"},{"key":"42","unstructured":"Spectrum Pharmaceuticals. (2014). Beleodaq\u00ae (belinostat) [Package insert]. Irvine, CA: Author."},{"key":"43","doi-asserted-by":"crossref","unstructured":"Stadler, W.M., Margolin, K., Ferber, S., McCulloch, W., & Thompson, J.A. (2006). A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clinical Genitourinary Cancer, 5, 57\u201360. doi:10.3816\/cgc.2006.n.018\u00a0","DOI":"10.3816\/CGC.2006.n.018"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Tan, J., Cang, S., Ma, Y., Petrillo, R.L., & Liu, D. (2010). Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of Hematology and Oncology, 3, 5. doi:10.1186\/1756-8722-3-5","DOI":"10.1186\/1756-8722-3-5"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Tang, D.H., & Malone, D.C. (2012). A network meta-analysis on the efficacy of serotonin type 3 receptor antagonists used in adults during the first 24 hours for postoperative nausea and vomiting prophylaxis. Clinical Therapeutics, 34, 282\u2013294. doi:10.1016\/j.clinthera.2012.01.007","DOI":"10.1016\/j.clinthera.2012.01.007"},{"key":"46","unstructured":"U.S. Food and Drug Administration. (2005). Guidance for industry: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Retrieved from http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm073153.pdf"},{"key":"47","unstructured":"U.S. Food and Drug Administration. (2016). FDA drug safety communication: Updated information on 32 mg intravenous ondansetron (Zofran) dose and pre-mixed ondansetron products. Retrieved from http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm330049.htm"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Whittaker, S.J., Demierre, M.F., Kim, E.J., Rook, A.H., Lerner, A., Duvic, M., . . . Kim, Y.H. (2010). Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 28, 4485\u20134491. doi:10.1200\/JCO.2010.28.9066","DOI":"10.1200\/JCO.2010.28.9066"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Yavas, C., Dogan, U., Yavas, G., Araz, M., & Ata, O.Y. (2012). Acute effect of palonosetron on electrocardiographic parameters in cancer patients: A prospective study. Supportive Care in Cancer, 20, 2343\u20132347. doi:10.1007\/s00520-011-1348-9","DOI":"10.1007\/s00520-011-1348-9"},{"key":"50","unstructured":""}],"container-title":["Oncology Nursing Forum"],"original-title":[],"link":[{"URL":"http:\/\/onf.ons.org\/onf\/43\/2\/nursing-roles-cardiac-safety-romidepsin-patients-t-cell-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:52:50Z","timestamp":1763754770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/onf\/43\/2\/nursing-roles-cardiac-safety-romidepsin-patients-t-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.1188\/16.onf.227-234","relation":{},"ISSN":["0190-535X","1538-0688"],"issn-type":[{"value":"0190-535X","type":"print"},{"value":"1538-0688","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,1]]}}}